Avdoralimab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Avdoralimab for COVID-19

1 study with 207 patients

Serious outcome risk

Avdoralimab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Avdoralimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−68%

Mortality (1)−68%

RCTs (1)−68%

Late (1)−68%

00.511.5+

← Avdoralimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 10 2022	Carvelli et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005683	Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])
Oct 10 2022	68% higher mortality (p=0.13). RCT 207 hospitalized COVID-19 patients showing no significant benefit with avdoralimab, a C5a receptor (C5aR1) inhibitor, compared to placebo across three cohorts of patients with varying COVID-19 severity.